Sugi Predict

Sugi Predict / Compounds / Sulbenox

Sulbenox

Sulbenox

SCHEMBL110252

NC(=O)NC1CCC(=O)c2sccc21

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ PDE10A Q9Y233 3/20 0.35
▸ CA12 O43570 3/20 0.34
▸ CA1 P00915 3/20 0.34
▸ CA2 P00918 3/20 0.34
▸ CA7 P43166 3/20 0.34
▸ CA9 Q16790 3/20 0.34
▸ CA14 Q9ULX7 3/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ MAPT P10636 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ CRBN Q96SW2 3/20 0.33
▸ MAPK10 P53779 2/20 0.33
▸ PDE4A P27815 1/20 0.32
▸ PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulbenox SCHEMBL11740934 1.00 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11535620 0.92 LMNA (0.45) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11261499 0.85 CA12 (0.45) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11746594 0.84 LMNA (0.40) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11525613 0.84 LMNA (0.46) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11478775 0.83 LMNA (0.61) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11523831 0.82 LMNA (0.45) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11554785 0.82 NPC1 (0.42) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11546081 0.82 L3MBTL1 (0.42) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL11741414 0.82 LMNA (0.39) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 707 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
WO-2012024611-A1 METHODS OF TREATING SARCOPENIA AND FRAILTY NATURAL ALTERNATIVES INTERNATIONAL, INC. (US) 2012-02-23 — — WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
EP-1718626-A4 SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD BRISTOL MYERS SQUIBB CO (US) 2009-08-19 — — EP claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
EP-1718626-A1 SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD Brystol-Myers Squibb Company (US) 2006-11-08 — — EP claimed
US-6951844-B2 Phenyl naphthol ligands for thyroid hormone receptor BRISTOL MYERS SQUIBB COMPANY (US) 2005-10-04 — — US claimed
US-20050187267-A1 Sulfonylpyrrolidine modulators of androgen receptor function and method BRISTOL-MYERS SQUIBB COMPANY 2005-08-25 — — US claimed
WO-2005077925-A1 SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2005-08-25 — — WO claimed
US-20050182105-A1 Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function BRISTOL-MYERS SQUIBB COMPANY 2005-08-18 — — US claimed
EP-0166025-A2 Non-antibiotic animal feed additive compositions AMERICAN CYANAMID COMPANY (US) 1986-01-02 — — EP claimed
US-4156670-A UREAS AND THIOUREAS, HERBICIDES, ANIMAL GROWTH REGULATORS AMERICAN CYANAMID COMPANY (US) 1979-05-29 — — US claimed
US-4144350-A 4,5,6,7-TETRAHYDRO-7-OXOBENZO(B)THIEN-4-YL UREAS AMERICAN CYANAMID COMPANY (US) 1979-03-13 — — US claimed
US-4060627-A Substituted tetrahydroiminobenzo(b)thien-4-ylureas as novel growth promoting compounds for animals AMERICAN CYANAMID COMPANY (US) 1977-11-29 — — US claimed
US-4036979-A ANIMAL GROWTH RATE ACCELERATOR AMERICAN CYANAMID COMPANY (US) 1977-07-19 — — US claimed
US-11612639-B2 Methods and compositions for rejuvenating skeletal muscle stem cells PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-03-28 — — US disclosed
US-3994924-A ANIMAL GROWTH PROMOTERS AMERICAN CYANAMID COMPANY (US) 1976-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187267-A1 Sulfonylpyrrolidine modulators of androgen receptor function and method NR3C2, AR, NR4A3 SMN1; SMN2 1949/4885NPC1 1126/4885RAB9A 3331/4885
US-20050182105-A1 Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function NR3C2, NR4A3, NR3C1 SMN1; SMN2 816/4885NPC1 2176/4885RAB9A 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.